What is the appropriate post‑exposure prophylaxis regimen for gonorrhea, chlamydia, and syphilis?

Post-Exposure Prophylaxis for Gonorrhea, Chlamydia, and Syphilis

For men who have sex with men (MSM) and transgender women at high risk for bacterial STIs, prescribe doxycycline 200 mg as a single dose to be taken within 72 hours after condomless oral, vaginal, or anal sex, with a maximum of 200 mg per 24-hour period. 1

Who Should Receive Doxycycline PEP

The 2024 CDC guidelines provide clear population-specific recommendations:

• Recommended for: MSM and transgender women who have had a bacterial STI (gonorrhea, chlamydia, or syphilis) diagnosed in the past 12 months 1
• May be considered for: MSM and transgender women without recent STI diagnosis but engaging in high-risk sexual activities 1
• Insufficient evidence: Cisgender women, cisgender heterosexual men, transgender men, and other queer/nonbinary persons—no recommendation can be made at this time 1

This represents a paradigm shift in STI prevention, with robust evidence showing 66-78% reduction in chlamydia and 73-76% reduction in syphilis in the target population 2. However, gonorrhea prevention is more modest (21% reduction) and appears to be declining over time due to emerging tetracycline resistance 3, 2.

Dosing and Administration Protocol

Specific instructions to provide patients:

• Take 200 mg doxycycline (any formulation) as soon as possible after sex, but no later than 72 hours post-exposure 1
• Maximum dose: 200 mg per 24-hour period (even with multiple sexual encounters) 1
• Take on a full stomach with a full glass of liquid 1
• Remain upright for 1 hour after taking to prevent esophagitis 1
• Separate dose by at least 2 hours from dairy products, antacids, and supplements containing calcium, iron, magnesium, or sodium bicarbonate 1

Prescribe enough doses based on anticipated sexual activity until the next follow-up visit (typically 3-6 months) 1.

Comprehensive Sexual Health Approach Required

Doxycycline PEP must be embedded within a broader prevention strategy, not used in isolation:

At initial visit:

• Screen for gonorrhea and chlamydia via NAAT at all anatomic sites of exposure (pharyngeal, rectal, urethral) 1
• Obtain serologic testing for syphilis 1
• Screen for HIV per CDC guidelines (every 3-6 months if not on HIV PrEP) 1
• Counsel on condom use, partner reduction, and HIV PrEP/PEP as indicated 1
• Discuss side effects: photosensitivity, esophagitis, GI intolerance, and potential antimicrobial resistance 1

At follow-up visits (every 3-6 months):

• Repeat STI screening at all exposure sites 1
• Assess for doxycycline side effects 1
• Re-evaluate ongoing need for doxy PEP 1
• Continue risk reduction counseling 1

Critical Effectiveness Data and Limitations

The evidence base is strong for certain populations but reveals important limitations:

Proven efficacy: Real-world data from southern California showed sustained 66.5% effectiveness against chlamydia and 60.7% against syphilis over 2+ years 3. Meta-analysis confirms chlamydia reduction (RR 0.22) and syphilis reduction (RR 0.24) with sufficient trial sequential analysis evidence 2.

Declining gonorrhea protection: A concerning 2026 study demonstrated rapid loss of gonorrhea effectiveness—from 42.3% pre-implementation to -15% (actually increased risk) by early 2025, correlating with tetM gene prevalence rising above 50% in circulating N. gonorrhoeae strains 3. When tetM prevalence exceeded 50%, effectiveness dropped to -8.5% 3. This suggests gonorrhea protection may be transient in many settings 3, 4.

Population gaps: No evidence supports use in cisgender women, heterosexual men, or transgender men 1. One real-world study actually found higher gonorrhea rates among doxy PEP users, likely reflecting risk compensation and local resistance patterns 4.

Antimicrobial Resistance Considerations

This remains the most contentious aspect of doxy PEP implementation. The evidence suggests a nuanced position:

• Short-term studies show no increase in multidrug-resistant bacteria prevalence (10.6% baseline vs 8.2% at 48 weeks) 5
• Tetracycline resistance in N. gonorrhoeae among doxy PEP users was similar to non-users (42.7% vs 46.3%) in one study 5
• However, population-level tetM expansion occurred rapidly after widespread implementation 3
• Expert consensus argues that concerns about resistance should not limit implementation, given the substantial morbidity from untreated syphilis and chlamydia, and that agricultural antibiotic use is a far larger driver of resistance 6

The Australian consensus took a more conservative stance, recommending doxy PEP primarily for syphilis prevention with limited duration of use 7.

Common Pitfalls to Avoid

1. Don't prescribe for populations without evidence: Resist pressure to prescribe for cisgender women or heterosexual men—the data simply don't exist 1

2. Don't oversell gonorrhea protection: Set realistic expectations that gonorrhea prevention is modest and may diminish over time, particularly in areas with high tetracycline resistance 3

3. Don't skip comprehensive STI screening: Doxy PEP is not a replacement for regular screening—maintain 3-6 month testing intervals 1

4. Don't forget drug interactions: Review all medications, particularly antacids and supplements 1

5. Don't prescribe indefinitely without reassessment: Evaluate ongoing need every 3-6 months through shared decision-making 1

Practical Implementation Algorithm

Step 1: Identify eligible patient (MSM or transgender woman with bacterial STI in past 12 months OR high-risk sexual behavior)

Step 2: Conduct baseline STI screening (NAAT at all exposure sites + syphilis serology) and HIV testing

Step 3: Counsel on benefits (strong chlamydia/syphilis prevention), limitations (modest/declining gonorrhea protection), and side effects

Step 4: Prescribe doxycycline 200 mg with clear dosing instructions and enough supply for 3-6 months based on sexual activity

Step 5: Schedule 3-6 month follow-up for repeat screening, side effect assessment, and need reassessment

Step 6: Monitor local gonorrhea resistance patterns if available—consider discontinuation if tetM prevalence exceeds 50% and gonorrhea is the primary concern

This evidence-based approach prioritizes the substantial reductions in syphilis and chlamydia morbidity while acknowledging the evolving landscape of gonorrhea resistance 1, 3, 2.